267 related articles for article (PubMed ID: 29326437)
1. Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
Ikink GJ; Boer M; Bakker ERM; Vendel-Zwaagstra A; Klijn C; Ten Hoeve J; Jonkers J; Wessels LF; Hilkens J
Oncogene; 2018 Mar; 37(12):1594-1609. PubMed ID: 29326437
[TBL] [Abstract][Full Text] [Related]
2. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
3. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
[TBL] [Abstract][Full Text] [Related]
4. IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation.
Ikink GJ; Boer M; Bakker ER; Hilkens J
Nat Commun; 2016 Nov; 7():13567. PubMed ID: 27876799
[TBL] [Abstract][Full Text] [Related]
5. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
6. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas.
Theodorou V; Boer M; Weigelt B; Jonkers J; van der Valk M; Hilkens J
Oncogene; 2004 Aug; 23(36):6047-55. PubMed ID: 15208658
[TBL] [Abstract][Full Text] [Related]
7. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
8. Genes affected by mouse mammary tumor virus (MMTV) proviral insertions in mouse mammary tumors are deregulated or mutated in primary human mammary tumors.
Callahan R; Mudunur U; Bargo S; Raafat A; McCurdy D; Boulanger C; Lowther W; Stephens R; Luke BT; Stewart C; Wu X; Munroe D; Smith GH
Oncotarget; 2012 Nov; 3(11):1320-34. PubMed ID: 23131872
[TBL] [Abstract][Full Text] [Related]
9. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
10. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
[TBL] [Abstract][Full Text] [Related]
11. β2-AR signaling controls trastuzumab resistance-dependent pathway.
Liu D; Yang Z; Wang T; Yang Z; Chen H; Hu Y; Hu C; Guo L; Deng Q; Liu Y; Yu M; Shi M; Du N; Guo N
Oncogene; 2016 Jan; 35(1):47-58. PubMed ID: 25798840
[TBL] [Abstract][Full Text] [Related]
12. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
[TBL] [Abstract][Full Text] [Related]
13. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.
Theodorou V; Kimm MA; Boer M; Wessels L; Theelen W; Jonkers J; Hilkens J
Nat Genet; 2007 Jun; 39(6):759-69. PubMed ID: 17468756
[TBL] [Abstract][Full Text] [Related]
14. Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Bose R; Kavuri SM; Searleman AC; Shen W; Shen D; Koboldt DC; Monsey J; Goel N; Aronson AB; Li S; Ma CX; Ding L; Mardis ER; Ellis MJ
Cancer Discov; 2013 Feb; 3(2):224-37. PubMed ID: 23220880
[TBL] [Abstract][Full Text] [Related]
15. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
[TBL] [Abstract][Full Text] [Related]
17. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
19. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
Kirouac DC; Du J; Lahdenranta J; Onsum MD; Nielsen UB; Schoeberl B; McDonagh CF
PLoS Comput Biol; 2016 Apr; 12(4):e1004827. PubMed ID: 27035903
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]